AU1923500A - Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis - Google Patents

Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis

Info

Publication number
AU1923500A
AU1923500A AU19235/00A AU1923500A AU1923500A AU 1923500 A AU1923500 A AU 1923500A AU 19235/00 A AU19235/00 A AU 19235/00A AU 1923500 A AU1923500 A AU 1923500A AU 1923500 A AU1923500 A AU 1923500A
Authority
AU
Australia
Prior art keywords
treatment
cryptosporidiosis
toxoplasmosis
metabolites
precursors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19235/00A
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T. Prendergast
Krupakar Paul Thadikonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbor Biosciences Inc
Original Assignee
Hollis Eden Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals Inc filed Critical Hollis Eden Pharmaceuticals Inc
Publication of AU1923500A publication Critical patent/AU1923500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU19235/00A 1998-11-27 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis Abandoned AU1923500A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11012798P 1998-11-27 1998-11-27
US60110127 1998-11-27
US12408799P 1999-03-11 1999-03-11
US60124087 1999-03-11
US12605699P 1999-03-23 1999-03-23
US60126056 1999-03-23
PCT/US1999/028080 WO2000032176A2 (en) 1998-11-27 1999-11-24 Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis

Publications (1)

Publication Number Publication Date
AU1923500A true AU1923500A (en) 2000-06-19

Family

ID=27380789

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19235/00A Abandoned AU1923500A (en) 1998-11-27 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis

Country Status (4)

Country Link
AP (1) AP2001002167A0 (en)
AU (1) AU1923500A (en)
CA (1) CA2352387A1 (en)
WO (1) WO2000032176A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (en) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Pharmaceutical preparation suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof.
JP2000508654A (en) * 1996-04-17 2000-07-11 プレンデルガスト，パトリック，ティー DHEA combination therapy
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Also Published As

Publication number Publication date
WO2000032176A3 (en) 2000-12-07
WO2000032176A2 (en) 2000-06-08
CA2352387A1 (en) 2000-06-08
AP2001002167A0 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
AU6325599A (en) New compounds, their preparation and use
AU6325899A (en) New compounds, their preparation and use
AU6190199A (en) New compounds, their preparation and use
AU6325799A (en) New compounds, their preparation and use
AU6190299A (en) New compounds, their preparation and use
AU6325699A (en) New compounds, their preparation and use
HUP0104943A3 (en) Controlled release formulation comprising gnrh-ii and its use
HUP9900163A2 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
AU6464400A (en) Combination treatment with il-1ra and diaryl sulphonyl urea compounds
HUP9902449A3 (en) Androstene derivatives, medicaments containing the same and their use
PL351250A1 (en) Antipicornaviral compounds, their preparation and use
AU1106195A (en) Heterocyclic compounds, their preparation and use
AU758325C (en) Imidazole compounds and medicinal use thereof
AU3159499A (en) Antigen preparation and use
AU3595099A (en) New compounds, their preparation and use
AU5056099A (en) Compounds for use in the treatment of inflammation
HK1042426A1 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other togaviruses
AU4994996A (en) Composition for the treatment of diarrhea, its use and its preparation
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
AU1154000A (en) Process and converter for the preparation of ammonia
AU7410900A (en) Alginate preparation and use of the same
IL142941A0 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of african and american trypanosomiasis
AU1923500A (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis
AU2601495A (en) Sequence-specific endonucleases, and preparation and use of same
AU3432900A (en) Colouring agent and the use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase